Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,

The Lancet · 2012 · 1.4K citations · 28 references

DOIFull text

Open access

Concepts

References

28